This PubMed entry documents an article published in Cancer Chemotherapy and Pharmacology on 2026 Sep 17 (volume 96, issue 1, page 107). The bibliographic record includes the DOI 10.1007/s00280-026-04952-3 and PubMed identifier (PMID) 42752932. The title as listed is “Outcomes of locally produced donor-derived anti-CD19 chimeric antigen receptor T-cells in relapsed or refractory B-cell acute lymphoblastic leukemia patients.”
The author list begins with Supavich Tannumsaeng and Usanarat Anurathapan and includes multiple coauthors. Institutional affiliations provided in the PubMed record are primarily tied to Mahidol University in Thailand and include:
Emails for certain corresponding authors are included in the PubMed entry. The supplied text lists a multi-institutional author group but does not present author-level contributions or corresponding author designation beyond email contacts shown on the record.
The article title indicates the study addresses clinical outcomes following administration of locally manufactured, donor-derived anti-CD19 chimeric antigen receptor (CAR) T-cells to patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The title signals a focus on donor-derived cellular therapy produced locally and applied in a relapsed/refractory pediatric or adult B-ALL population, but the PubMed clip provided here does not include additional descriptive text about the patient population, indications, or endpoints.
These identifiers can be used to retrieve the full bibliographic record, publisher abstract, or full text through institutional access, publisher platforms, or library services.
The portion of the PubMed page supplied here contains bibliographic metadata, author names, affiliations, and navigation elements but does not include the article abstract, methods, numerical results, safety data, efficacy outcomes, or authors’ conclusions. Specifics commonly expected in an abstract — such as sample size, study design (prospective vs retrospective), conditioning regimens, manufacturing process for donor-derived CAR T-cells, response rates, duration of remission, survival metrics, incidence and grading of cytokine release syndrome or neurotoxicity, and statistical analyses — are not present in the provided text.
The supplied source text does not provide the following study elements:
Because these elements are not in the clipped PubMed text, they cannot be summarized or paraphrased here. Any attempt to describe study outcomes or recommendations would require consultation of the full abstract or the published article itself.
To review study design, patient-level data, results, safety findings, and authors’ conclusions, access to the full-text article or the complete PubMed abstract is required. Use one of the following approaches:
Note: This summary and rewritten content are strictly limited to the bibliographic and administrative information present in the supplied PubMed page text. The provided source did not include the article abstract or any study results; therefore, no clinical outcomes, numerical data, or study conclusions are reported here. For definitive clinical details on the use of locally produced donor-derived anti-CD19 CAR T-cells in relapsed or refractory B-ALL, consult the full published article.